P/E ratio for Alkermes (ALKS)
P/E ratio as of April 2024 (TTM): 18.5
According to Alkermes's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.4692. At the end of 2022 the company had a P/E ratio of -27.2.
P/E ratio history for Alkermes from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -27.2 | -64.89% |
| 2021 | -77.5 | 172.37% |
| 2020 | -28.5 | 75.82% |
| 2019 | -16.2 | -51.17% |
| 2018 | -33.2 | -37.6% |
| 2017 | -53.1 | 30.98% |
| 2016 | -40.6 | -22.32% |
| 2015 | -52.2 | -82.16% |
| 2014 | -293 | -200.82% |
| 2013 | 290 | -680.23% |
| 2012 | -50.1 | 75.88% |
| 2011 | -28.5 | 13.56% |
| 2010 | -25.1 | 9.19% |
| 2009 | -23.0 | -390.93% |
| 2008 | 7.89 | -5.37% |
| 2007 | 8.34 | -93.14% |
| 2006 | 122 | -208.07% |
| 2005 | -112 | 650.34% |
| 2004 | -15.0 | 76.54% |
| 2003 | -8.49 | 97.71% |
| 2002 | -4.29 | -86.48% |
| 2001 | -31.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -44.35% | 🇺🇸 USA |
 Novartis NVS | 24.9 | 34.75% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -26.00% | 🇺🇸 USA |
 Sanofi SNY | 14.5 | -21.50% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 12.1 | -34.75% | 🇺🇸 USA |
 AstraZeneca AZN | 34.5 | 86.93% | 🇬🇧 UK |
 Zogenix ZGNX | -6.56 | -135.49% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -100.37% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.59 | -135.68% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.